PT  - JOURNAL ARTICLE
AU  - Zhang, Xiao-Yu
AU  - Zhang, Lin
AU  - Zhao, Yang
AU  - Li, Wei-Xia
AU  - Wu, Hai-Bing
AU  - Ling, Yun
AU  - Qian, Zhi-Ping
AU  - Jin, Yin-Peng
AU  - Fu, Qing-Chun
AU  - Li, Xin-Yan
AU  - Zhang, Yi
AU  - Huang, Yu-Xian
AU  - Chen, Liang
TI  - Risk assessment and prediction of severe or critical illness of COVID-19 in the elderly
AID  - 10.1101/2020.05.11.20094383
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.11.20094383
4099  - http://medrxiv.org/content/early/2020/05/15/2020.05.11.20094383.short
4100  - http://medrxiv.org/content/early/2020/05/15/2020.05.11.20094383.full
AB  - Background This study aims to investigate the clinical characteristics and risk prediction of severe or critical events of COVID-19 in the elderly patients in China.Methods The clinical data of COVID-19 in the elderly patients admitted to the Shanghai Public Health Clinical Center during the period of January 20, 2020 to March 16, 2020 were collected. A retrospective cohort study design was conducted to screen out independent factors through Cox univariable regression analysis and multivariable regression analysis, and the efficacy of risk prediction of severe or critical illness was examined through the receiver operating characteristic (ROC) curve.Results A total of 110 elderly patients with COVID-19 were enrolled. 52 (47.3%) were males and 21 (19.1%) had severe or critical illness. Multivariable regression analysis showed that CD4 cells and D-dimer were independent risk factors. D-dimer, CD4 cells, and D-dimer/CD cells ratios with cut off values of 0.65 (mg/L), 268 (cell/ul) and 431 were in the prediction of severe or critical illness of the elderly COVID-19. The AUC value of D-dimer, CD4 cells, CD4 cells/D-dimer ratio, the tandem group and the parallel group were 0.703, 0.804, 0.794, 0.812 and 0.694, respectively.Conclusions D-dimer, CD4 cells and their combination have risk assessment value in predicting severe or critical illness of COVID-19 in the elderly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study was supported by the Shanghai Public Health Clinical Center for data access.